<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF"><gtr:id>AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF</gtr:id><gtr:name>Cypralis Limited</gtr:name><gtr:address><gtr:line1>FYFIELD BUSINESS AND RESEARCH PARK , FYFIELD ROAD</gtr:line1><gtr:city>ONGAR</gtr:city><gtr:postCode>CM5 0GS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF</gtr:id><gtr:name>Cypralis Limited</gtr:name><gtr:address><gtr:line1>FYFIELD BUSINESS AND RESEARCH PARK , FYFIELD ROAD</gtr:line1><gtr:city>ONGAR</gtr:city><gtr:postCode>CM5 0GS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>119996.0</gtr:offerGrant><gtr:projectCost>199937.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DD56E19D-764A-45E7-9DBA-A8B034CDA66D"><gtr:id>DD56E19D-764A-45E7-9DBA-A8B034CDA66D</gtr:id><gtr:firstName>carol</gtr:firstName><gtr:surname>austin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132035"><gtr:id>4C3924B0-E6B6-4D7A-899C-12B1CB967D9F</gtr:id><gtr:title>Selective inhibitors of cyclophilin D for the treatment of acute pancreatitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132035</gtr:grantReference><gtr:abstractText>The project will identify novel, selective inhibitors of cyclophilin D which is an attractive target for the treatment of acute pancreatitis, an orphan disease with no available drug therapies. Cyclosporin, a marketed drug which is known to inhibit cyclophilin D, cannot be used for treating acute pancreatitis because of its other properties including immuno-suppression. The proposed feasibility study aims to achieve selectivity for cyclophilin D, in order to provide a robust start point for a drug discovery campaign.</gtr:abstractText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>119996</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132035</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>